Show simple item record

dc.contributor.authorShahneh, FZ
dc.contributor.authorBabalo, Z
dc.contributor.authorBaradaran, B
dc.contributor.authorSepehr, KS
dc.date.accessioned2018-08-26T08:58:40Z
dc.date.available2018-08-26T08:58:40Z
dc.date.issued2012
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/54721
dc.description.abstractBehçet's disease is a chronic relapsing multi-organ inflammatory disorder characterized as a triad of oral and genital ulcers, uveitis. Characteristic manifestations of Behçet's disease are joints, skin, central nervous system and gastrointestinal tract involvement. Behçet's disease has a complicated genetic etiology. However, epidemiological studies recommend that genetic factors have a significant role in its pathogenesis, the same as other autoinflammatory disorders. Antigenic stimuli, antigen-presenting cells, T cells, monocyte, neutrophil and endothelial cells are most important parts of the pathology of the disease. Inflammatory response was triggered by an infectious agent in a genetically susceptible host. Understanding the pathogenesis based on the molecular mechanism of the disease highlights the new therapeutic modalities. Enhanced inflammatory activity and over-expression of proinflammatory cytokines are the striking features of Behçet's disease, and they are accordant with the result in other auto inflammatory disorders. Moreover, there is evidence of antigen-driven immune response in Behçet's disease, but it probably advances in further innate immune reactivity. New therapeutic modalities target specific and nonspecific suppression of the immune system. The diagnosis is a clinical one, and although there is no single laboratory test enough for the diagnosis of Behçet's disease. In this paper, a new aspect of the studies on genetic susceptibility, immunopathogenesis of Behçet's disease and novel treatment modalities will be discussed.
dc.language.isoEnglish
dc.relation.ispartofPostepy Dermatologii i Alergologii
dc.subjectadalimumab
dc.subjectalemtuzumab
dc.subjectcanakinumab
dc.subjectcholera toxin B subunit
dc.subjectcyclophosphamide
dc.subjectcytokine
dc.subjectetanercept
dc.subjectinfliximab
dc.subjectmethotrexate
dc.subjectprednisone
dc.subjectregeneron
dc.subjectrilonacept
dc.subjectrituximab
dc.subjecttocilizumab
dc.subjectunclassified drug
dc.subjectantigen presenting cell
dc.subjectBehcet disease
dc.subjectendothelium cell
dc.subjectgenetic susceptibility
dc.subjectgenital ulcer
dc.subjectheredity
dc.subjecthuman
dc.subjectimmunopathogenesis
dc.subjectinnate immunity
dc.subjectmolecular mechanics
dc.subjectmonocyte
dc.subjectneutrophil
dc.subjectreview
dc.subjectT lymphocyte
dc.subjectuveitis
dc.titleInsights into Behçet's disease
dc.typeArticle
dc.citation.volume29
dc.citation.issue6
dc.citation.spage461
dc.citation.epage466
dc.citation.indexScopus
dc.identifier.DOIhttps://doi.org/10.5114/pdia.2012.32395


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record